PTH-A particularly tricky hormone: Why measure it at all in kidney patients?

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 2, 2013, Pages 299-312

  Garrett, Giorgia ^a   Sardiwal, Sunita ^a   Lamb, Edmund J ^a   Goldsmith, David J A ^b  

^a EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITRIOL; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; FIBROBLAST GROWTH FACTOR 23; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

ALBRIGHT SYNDROME; ARTICLE; BONE TURNOVER; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; GENETIC VARIABILITY; HEALTH; HORMONE DETERMINATION; HUMAN; IMMUNORADIOMETRIC ASSAY; META ANALYSIS (TOPIC); OSTEOLYSIS; OUTCOME ASSESSMENT; PHYSIOLOGY; PREDICTIVE VALUE; RADIOIMMUNOASSAY; SKELETON;

DIAGNOSTIC TESTS, ROUTINE; HEMATOLOGIC TESTS; HUMANS; PARATHYROID HORMONE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84875043157     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09580911     Document Type: Article

References (94)

1. Mallory Expedition. Available at: http://www.malloryexpedition. com/george.htm. Accessed on March 9, 2011
2. Felsenfeld AJ, Rodríguez M, Aguilera-Tejero E: Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism. Clin J Am Soc Nephrol 2: 1283-1305, 2007
3. Kraenzlin ME, Meier C: Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol 7: 647-656, 2011
4. Lamb EJ, Vickery S, Ellis AR: Parathyroid hormone, kidney disease, evidence and guidelines. Ann Clin Biochem 44(Pt 1): 1-4, 2007
5. Massry SG: Is parathyroid hormone a uremic toxin? Nephron 19: 125-130, 1977
6. Rodriguez M, Lorenzo V: Parathyroid hormone, a uremic toxin. Semin Dial 22: 363-368, 2009
7. Sprague SM: Renal bone disease. Curr Opin Endocrinol Diabetes Obes 17: 535-539, 2010
8. Covic A, Kanbay M, Voroneanu L, Turgut F, Serban DN, Serban IL, Goldsmith DJ: Vascular calcification in chronic kidney disease. Clin Sci (Lond) 119:111-121, 2010.
9. Ketteler M, Rothe H, Krüger T, Biggar PH, Schlieper G: Mechanisms and treatment of extraosseous calcification in chronic kidney disease. Nat Rev Nephrol 7: 509-516, 2011
10. Moe S, Drüeke T, CunninghamJ, GoodmanW, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G; Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945-1953, 2006
11. LondonG, CoyneD, Hruska K, MallucheHH, Martin KJ: The new kidney disease: Improving global outcomes (KDIGO) guidelines-expert clinical focus on bone and vascular calcification. Clin Nephrol 74: 423-432, 2010
12. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71: 31-38, 2007
13. SpasovskiG: Strategies tomanage low-bone turnover. Nefrologia 29: 295-297, 2009
14. Frazão JM, Martins P: Adynamic bone disease: Clinical and therapeutic implications. Curr OpinNephrolHypertens 18: 303-307, 2009
15. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH: Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 26: 622-631, 1995
16. Fletcher S, Jones RG, Rayner HC, Harnden P, Hordon LD, Aaron JE, Oldroyd B, Brownjohn AM, Turney JH, Smith MA: Assessment of renal osteodystrophy in dialysis patients: Use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 75: 412-419, 1997
17. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic KidneyDisease-Mineral and BoneDisorder (CKD-MBD). Kidney Int Suppl 113: S1-S130, 2009
18. Goldsmith D, Ritz E, Covic A: Vascular calcification: A stiff challenge for the nephrologist: Does preventing bone disease cause arterial disease? Kidney Int 66: 1315-1333, 2004
19. Isakova T, Xie H, YangW, Xie D, Anderson AH, Scialla J, Wahl P, Gutié rrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort(CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011
20. Goldsmith DJ, CunninghamJ: Mineralmetabolismand vitaminD in chronic kidney disease-more questions than answers. Nat Rev Nephrol 7: 341-346, 2011
21. Ritz E, Stefanski A, Rambausek M: The role of the parathyroid glands in the uremic syndrome. Am J Kidney Dis 26: 808-813, 1995
22. Kanbay M, Goldsmith D, Akcay A, Covic A: Phosphate-the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: A systematic review. Blood Purif 27: 220-230, 2009
23. Bhuriya R, Li S, Chen SC, McCullough PA, Bakris GL: Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: An analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 53[Suppl 4]: S3-S10, 2009
24. Hagström E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundström J, Melhus H, Held C, Lind L, Michaë lsson K, Arnlöv J: Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 119: 2765-2771, 2009
25. Kestenbaum B, Katz R, de Boer I, Hoofnagle A, Sarnak MJ, Shlipak MG, Jenny NS, Siscovick DS: Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol 58: 1433-1441, 2011
26. Ahlström T, Hagström E, Larsson A, Rudberg C, Lind L, Hellman P: Correlation between plasma calcium, parathyroid hormone (PTH) and the metabolic syndrome (MetS) in a community-based cohort of men and women. Clin Endocrinol (Oxf) 71: 673-678, 2009
27. Kalantar-Zadeh K, Shah A, Duong U, Hechter RC, Dukkipati R, Kovesdy CP: Kidney bone disease and mortality in CKD: Revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl 117: S10-21, 2010
28. Wanner C, Krane V, Mä rzW, Olschewski M, Mann JF, Ruf G, Ritz E;GermanDiabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005
29. Drechsler C, Krane V, Grootendorst DC, Ritz E, Winkler K, März W, Dekker F, Wanner C; German Diabetes and Dialysis Study Investigators: The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. NephrolDial Transplant 24: 3151-3157, 2009
30. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF: Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: A systematic reviewand meta-analysis. JAMA 305: 1119-1127, 2011
31. Goldsmith D: Extraordinary popular delusions and the madness of crowds: Puncturing the epoetin bubble-lessons for the future. Nephrol Dial Transplant 26: 24-28, 2011
32. Zidehsarai MP, Moe SM: Review article: Chronic kidney diseasemineral bone disorder: Have we got the assays right? Nephrology (Carlton) 14: 374-382, 2009
33. Brown RC, Aston JP, Weeks I, Woodhead JS: Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay. J Clin Endocrinol Metab 65: 407-414, 1987
34. Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, Keutmann HT, Wang CA, Potts JT Jr, Segre GV: Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33: 1364-1367, 1987
35. Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barré M, D'Amour P: Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTHassay in renal failure: Importance in the interpretation of PTH values. J Clin Endocrinol Metab 81: 3923-3929, 1996
36. Gao P, Scheibel S, D'Amour P, JohnMR, Rao SD, Schmidt-Gayk H, Cantor TL: Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: Implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16: 605-614, 2001
37. Souberbielle JC, Roth H, Fouque DP: Parathyroid hormone measurement in CKD. Kidney Int 77: 93-100, 2010
38. Huan J, Olgaard K, Nielsen LB, Lewin E: Parathyroid hormone 7-84 induces hypocalcemia and inhibits the parathyroid hormone 1-84 secretory response to hypocalcemia in rats with intact parathyroid glands. J Am Soc Nephrol 17: 1923-1930, 2006
39. Friedman PA, Goodman WG: PTH(1-84)/PTH(7-84): A balance of power. Am J Physiol Renal Physiol 290: F975-F984, 2006
40. Malluche HH, Monier-Faugere MC: Pth 1-84, Pth fragments and bone turnover. Am J Kidney Dis 41: 1127, 2003
41. Monge M, Jean G, Bacri JL, Lemaitre V, Masy E, Joly D, Souberbielle JC: Higher parathyroid hormone (PTH) concentrations with the Architect PTH assay than with the Elecsys assay in hemodialysis patients, and a simple way to standardize these two methods. Clin Chem Lab Med 47: 362-366, 2009
42. Joly D, Drueke TB, Alberti C, Houillier P, Lawson-Body E, Martin KJ, Massart C, Moe SM, Monge M, Souberbielle JC: Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: A cross-sectional study. Am J Kidney Dis 51: 987-995, 2008
43. Cantor T, Yang Z, CaraianiN, Ilamathi E: Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: Implication for treatment decisions. Clin Chem 52:1771-1776, 2006
44. Ellis A, Almond A, Walker S: Current PTH immunoassays do not adequately meet the needs of patients with chronic kidney disease. Ann Clin Biochem 49: 63-67, 2012
45. D'Amour P, Brossard JH, Räkel A, Rousseau L, Albert C, Cantor T: Evidence that the amino-terminal composition of non-(1-84) parathyroid hormone fragments starts before position 19. Clin Chem 51: 169-176, 2005
46. World Health Organization: WHO International Collaborative Study of the proposed 1st International Standard for Parathyroid Hormone 1-84, human, recombinant. Available at: http://whqlibdoc.who.int/hq/2009/WHO_BS_09.2115_eng.pdf. Accessed March 9, 2011
47. Sturgeon CM, Sprague SM, MetcalfeW: Variation in parathyroid hormone immunoassay results-a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant 26: 3440-3445, 2011
48. Teal TK, Reed M, Stevens PE, Lamb EJ: Stability of parathyroid hormone ex vivo in haemodialysis patients. Ann Clin Biochem 40: 191-193, 2003
49. Teal TK, Wood JL, Stevens PE, Lamb EJ: Stability of Bio-Intact (1-84) parathyroid hormone ex vivo in serum and EDTA plasma from hemodialysis patients. Clin Chem 50: 1713-1714, 2004
50. English E, McFarlane I, Taylor KP, Halsall DJ: The effect of potassium EDTA on the stability of parathyroid hormone in whole blood. Ann Clin Biochem 44: 297-299, 2007
51. Cavalier E, Delanaye P, Carlisi A, Krzesinski JM, Chapelle JP: Stability of intact parathyroid hormone in samples from hemodialysis patients. Kidney Int 72: 370-372, 2007
52. Gardham C, Stevens PE, Delaney MP, LeRoux M, Coleman A, Lamb EJ: Variability of parathyroid hormone and othermarkers of bone mineral metabolism in patients receiving hemodialysis. Clin J Am Soc Nephrol 5: 1261-1267, 2010
53. Vulpio C, Bossola M, Speranza D, Zuppi C, Luciani G, Di Stasio E: Influence of blood sampling site on intact parathyroid hormone concentrations in hemodialysis patients. Clin Chem 56: 489-490, 2010
54. Brossard JH, Lepage R, Cardinal H, Roy L, Rousseau L, Dorais C, D'Amour P: Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 46: 697-703, 2000
55. Wesseling-Perry K, Harkins GC, Wang HJ, Elashoff R, Gales B, Horwitz MJ, Stewart AF, Jüppner H, Salusky IB. The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: A potential role for PTH(7-84). J Clin EndocrinolMetab 95: 2772-2780, 2010
56. Moore C, Yee J, Malluche H, Rao DS, Monier-Faugere MC, Adams E, Daramola-Ogunwuyi O, Fehmi H, Bhat S, Osman-Malik Y: Relationship between bone histology and markers of bone andmineral metabolismin African-American hemodialysis patients. Clin J Am Soc Nephrol 4: 1484-1493, 2009
57. Drechsler C, Grootendorst DC, Boeschoten EW, Krediet RT, Wanner C, Dekker FW; NECOSAD study group: Changes in parathyroid hormone, body mass index and the association with mortality in dialysis patients. Nephrol Dial Transplant 26: 1340-1346, 2011
58. Haarhaus M, FernströmA, MagnussonM, Magnusson P: Clinical significance of bone alkaline phosphatase isoforms, including the novel B1x isoform, in mild to moderate chronic kidney disease. Nephrol Dial Transplant 24: 3382-3389, 2009
59. Drechsler C, Verduijn M, Pilz S, Krediet RT, Dekker FW, Wanner C, Ketteler M, Boeschoten EW, Brandenburg V; NECOSAD Study Group: Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol 6: 1752-1759, 2011
60. Tanzy ME, Camacho PM: Effect of vitamin D therapy on bone turnover markers in postmenopausal women with osteoporosis and osteopenia. Endocr Pract 17: 873-879, 2011
61. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF: Meta-analysis: Vitamin D compounds in chronic kidney disease. Ann Intern Med 147: 840-853, 2007
62. Regidor DL, Kovesdy CP, Mehrotra R, Rambod M, Jing J, McAllister CJ, Van Wyck D, Kopple JD, Kalantar-Zadeh K: Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 19: 2193-2203, 2008
63. Shantouf R, Kovesdy CP, Kim Y, Ahmadi N, Luna A, Luna C, Rambod M, Nissenson AR, Budoff MJ, Kalantar-Zadeh K: Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol 4: 1106-1114, 2009
64. Hutchison AJ, Whitehouse RW, Boulton HF, Adams JE, Mawer EB, Freemont TJ, Gokal R: Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 44: 1071-1077, 1993
65. Ureña P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC: Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 7: 506-512, 1996
66. Tolouian R, Hernandez GT, Chiang WY, Gupta A: A new approach for evaluating bone turnover in chronic kidney disease. Eur J Intern Med 21: 230-232, 2010
67. Magnusson P, Larsson L, Magnusson M, Davie MW, Sharp CA: Isoforms of bone alkaline phosphatase: Characterization and origin in human trabecular and cortical bone. J Bone Miner Res 14: 1926-1933, 1999
68. Manghat P, Fraser WD, Wierzbicki AS, Fogelman I, Goldsmith DJ, Hampson G: Fibroblast growth factor-23 is associated with C-reactive protein, serumphosphate and bonemineral density in chronic kidney disease. Osteoporos Int 21: 1853-1861, 2010
69. Iimori S, Mori Y, AkitaW, Kuyama T, Takada S, Asai T, Kuwahara M, Sasaki S, Tsukamoto Y: Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients-a single-center cohort study. Nephrol Dial Transplant27: 345-351, 2012
70. Coleman A, Delaney M, Stevens PE, Sardiwal S, Lamb E: Bonespecific alkaline phosphatase concentrations are less variable than parathyroid hormone concentrations amongst stable hemodialysis patients. Kidney Int 2012, in press
71. Malluche HH, Monier-Faugere MC, Wang G, Frazã O JM, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG: An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 69: 269-278, 2008
72. Couttenye MM, D'Haese PC, Van Hoof VO, Lemoniatou E, Goodman W, Verpooten GA, De Broe ME: Low serum levels of alkaline phosphatase of bone origin: A good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 11: 1065-1072, 1996
73. Lew JI, Irvin GL 3rd: Focused parathyroidectomy guided by intraoperative parathormone monitoring does not miss multiglandular disease in patients with sporadic primary hyperparathyroidism: A 10-year outcome. Surgery 146: 1021-1027, 2009
74. Padhi D, Harris R: Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet 48: 303-311, 2009
75. Cavalier E, Delanaye P, Vranken L, Bekaert AC, Carlisi A, Chapelle JP, Souberbielle JC: Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: Importance of the reference (normal) values [published online ahead of print September 22, 2011]. Nephrol Dial Transplant doi:10.1093/ndt/gfr535
76. Gerakis A, Hutchison AJ, Apostolou T, Freemont AJ, Billis A: Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant 11: 2430-2438, 1996
77. Coen G, Ballanti P, Bonucci E, Calabria S, Centorrino M, Fassino V, Manni M, Mantella D, Mazzaferro S, Napoletano I, Sardella D, Taggi F: Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. NephrolDial Transplant 13: 2294-2302, 1998
78. Carmen Sánchez M, Auxiliadora Bajo M, Selgas R, Mate A, Millán I, Eugenia Martínez M, López-Barea F: Parathormone secretion in peritoneal dialysis patients with adynamic bone disease. Am J Kidney Dis 36: 953-961, 2000
79. Coen G, Ballanti P, Bonucci E, Calabria S, Costantini S, Ferrannini M, Giustini M, Giordano R, Nicolai G, Manni M, Sardella D, Taggi F: Renal osteodystrophy in predialysis and hemodialysis patients: Comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron 91: 103-111, 2002
80. Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, Nicolai GA, Fischer MS, Lifrieri F, Manni M, Morosetti M, Moscaritolo E, Sardella D: PTH1-84 and PTH"7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 40: 348-354, 2002
81. Bervoets AR, Spasovski GB, Behets GJ, Dams G, Polenakovic MH, Zafirovska K, Van Hoof VO, De Broe ME, D'Haese PC: Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis 41: 997-1007, 2003
82. Spasovski GB, Bervoets AR, Behets GJ, Ivanovski N, Sikole A, Dams G, Couttenye MM, De Broe ME, D'Haese PC: Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant 18: 1159-1166, 2003
83. CoenG, Mantella D, Manni M, Balducci A, Nofroni I, SardellaD, Ballanti P, Bonucci E: 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int 68: 1840-1848, 2005
84. Gal-Moscovici A, Popovtzer MM: New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 63: 284-289, 2005
85. Lehmann G, Stein G, Hüller M, Schemer R, Ramakrishnan K, Goodman WG: Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int 68: 1206-1214, 2005
86. Barreto FC, Barreto DV, Moysés RM, Neves KR, Canziani ME, Draibe SA, Jorgetti V, Carvalho AB: K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 73: 771-777, 2008
87. Yamada S, InabaM, Kurajoh M, Shidara K, Imanishi Y, Ishimura E, Nishizawa Y: Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: Independence from renal dysfunction. Clin Endocrinol (Oxf) 69: 189-196, 2008
88. Ferreira A, Frazão JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH; Sevelamer Study Group: Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 19: 405-412, 2008
89. Lehmann G, Ott U, Kaemmerer D, Schuetze J, Wolf G: Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease Stages 3-5. Clin Nephrol 70: 296-305, 2008
90. Coen G, Ballanti P, Mantella D, Manni M, Lippi B, Pierantozzi A, Di Giulio S, Pellegrino L, Romagnoli A, Simonetti G, Splendiani G: Bone turnover, osteopenia and vascular calcifications in hemodialysis patients. A histomorphometric and multislice CT study. Am J Nephrol 29: 145-152, 2009
91. Fehmi H, Osman Y, Bhat S, Nguyen K, Daramola O, Cantor T, Monier-Faugere MC, Yee J, Malluche HH: Absence of adynamic bone disease in African-Americans with CKD stage 5 after 3 years of vitamin D therapy guided by iPTH and the PTH-(1-84)/N-terminally truncated PTH fragments ratio. Clin Nephrol 71: 267-275, 2009
92. Herberth J, Branscum AJ, Mawad H, Cantor T, Monier-Faugere MC, Malluche HH: Intact PTH combined with the PTH ratio for diagnosis of bone turnover in dialysis patients: A diagnostic test study. Am J Kidney Dis 55: 897-906, 2010
93. Fahrleitner-Pammer A, Herberth J, Browning SR, Obermayer-Pietsch B, Wirnsberger G, Holzer H, Dobnig H, Malluche HH: Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res 23: 1850-1858, 2008
94. Broyles DL, Nielsen RG, Bussett EM, Lu WD, Mizrahi IA, Nunnelly PA, Ngo TA, Noell J, Christenson RH, Kress BC: Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase. Clin Chem 44: 2139-2147, 1998